OVERVIEW
In this 60-minute, live, interactive symposium, faculty will discuss lymphocyte-activation gene 3 (LAG3) inhibitors for use in metastatic melanoma, including how they differ from other checkpoint inhibitors, the clinical significance of recent clinical trial data, approaches to identify and manage immune-related adverse events (AEs), and patient eligibility considerations. An emphasis will be placed on the patient voice and how nurses and nurse practitioners (NPs) play a critical role in involving patients in shared decision making. Interactive polling questions will be included throughout the program to engage the audience participants.
GOAL STATEMENT
The goal of this activity is for learners to be better able to help oncology nurses and NPs better leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the[LIST][ITEM]Safety data associated with LAG3 inhibitors in metastatic melanoma[ITEM]Strategies used to facilitate shared decision-making (SDM) practices in care of patients with metastatic melanoma potentially eligible for or already receiving LAG3 inhibitors[/LIST]Have greater competence related to[LIST][ITEM]Mitigating potential adverse events experienced by patients receiving LAG3 inhibitors for metastatic melanoma[/LIST]Demonstrate greater confidence in their ability to[LIST][ITEM]Serve as a trusted liaison between the patient and other members of the melanoma treatment team[/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Nurses[/bold] Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.
San Antonio Marriott Rivercenter
Marriott Rivercenter Grand Ballroom A-F
101 Bowie Street
San Antonio, Texas, 78205
United States
Meeting space has been assigned to provide a Symposium supported by Regeneron Pharmaceuticals, Inc. during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26 – April 30, 2023 in San Antonio, TX. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Supported by an independent educational grant from [bold]Regeneron Pharmaceuticals Inc[/bold].